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Objectives: Carotid angioplasty and stenting (CAS) has been proposed as an alternative to carotid endarterectomy (CEA)
in patients excluded from the North American Symptomatic Carotid Endarterectomy Trial and the Asymptomatic
Carotid Atherosclerosis Study and in those considered at high risk for CEA. In light of recently released CAS data in
patients at high risk, we reviewed our experience with CEA.
Methods: The records for consecutive patients who underwent CEA between 1998 and 2002 were retrospectively
reviewed, and risk was stratified according to inclusion and exclusion criteria from a “high-risk” or CAS-CEA trial, The
Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial.
Results: Of 776 CEAs performed, 323 (42%) were considered high risk, on the basis of criteria including positive stress
test (n  109, 14%), age older than 80 years (n  85, 11%), contralateral carotid occlusion (n  66, 9%), pulmonary
dysfunction (n  56, 7%), high cervical lesion (n  36, 5%), and repeat carotid operation (n  27, 3%). Other high-risk
criteria included recent myocardial infarction (MI), cardiac surgery, or class III or IV cardiac status; left ventricular
ejection fraction less than 30%; contralateral laryngeal palsy; and previous neck irradiation (each <1.5%). Clinical
presentation was similar in the high-risk and low-risk groups: asymptomatic (73% versus 73%), transient ischemic attack
(23% vs 22%), and previous stroke (4% vs 5%). The overall postoperative stroke rate was 1.4% (symptomatic, 2.9%;
asymptomatic, 0.9%). Comparison of high-risk and low-risk CEAs demonstrated no statistical difference in the stroke
rate. Factors associated with significantly increased stroke risk included cervical radiation therapy, class III or IV angina,
symptomatic presentation, and age 60 years or younger. Overall mortality was 0.3% (symptomatic, 0.5%; asymptomatic,
0.2%), not significantly different between the high-risk (0.6%) and low-risk groups (0.0%). Non-Q-wave MI was more
frequent in the high-risk group (3.1 vs 0.9%; P < .05). A composite cluster of adverse clinical events (death, stroke, MI)
was more frequent in the symptomatic high-risk group (9.3% vs 1.6%; P < .005), but not in the asymptomatic cohort.
There was a trend for more major cranial nerve injuries in patients with local risk factors, such as high carotid bifurcation,
repeat operation, and cervical radiation therapy (4.6% vs 1.7%; P < .13). In 121 patients excluded on the basis of
synchronous or immediate subsequent operations, who also would have been excluded from SAPPHIRE, the overall rates
for stroke (1.65%; P .69), death (1.65%; P .09), and MI (0.83%; P .71) were not significantly different from those
in the study population.
Conclusions: CEA can be performed in patients at high risk, with stroke and death rates well within accepted standards.
These data question the use of CAS as an alternative to CEA, even in patients at high risk. (J Vasc Surg 2004;39:958-66.)The safety and efficacy of carotid endarterectomy
(CEA) in the treatment of high-grade symptomatic and
asymptomatic carotid artery stenosis have been demon-
strated in two large-scale prospective randomized trials, the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET) and the Asymptomatic Carotid Athero-
sclerosis Study (ACAS).1-3 These trials included patients
who were selected on the basis of good medical risk, long
life expectancy, and absence of previous ipsilateral CEA or
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doi:10.1016/j.jvs.2003.12.037958radiation treatment (ACAS only). A significant portion of
patients currently undergoing CEA would, however, be
ineligible for the NASCET and ACAS trials, mainly because
of advanced age and medical comorbid conditions. This
triggered multiple nonrandomized studies, which demon-
strated the safety of CEA in a variety of high-risk subsets.4-6
Carotid artery angioplasty and stenting (CAS) is an
evolving technique for stroke prophylaxis. There are cur-
rently no data to support the long-term efficacy of CAS in
preventing stroke and death. Short-term clinical outcome
of CAS has been the subject of multiple randomized and
nonrandomized studies. The Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterec-
tomy trial (SAPPHIRE; Cordis Corp, Miami Lakes, Fla) is
the first controlled, prospective randomized trial of CAS
with a cerebral protection device.7 Only patients at high
risk were enrolled in the SAPPHIRE trial. Preliminary data
suggest that CAS with a cerebral protection device, when
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30-day adverse clinical events, defined as a combined end
point of stroke, death, and myocardial infarction (MI).
In this study we report our experience with CEA in
SAPPHIRE-eligible patients at high risk.
METHODS
Records for all consecutive patients undergoing CEA
performed by members of the Division of Vascular Surgery
at the Mayo Clinic, Rochester, Minn, between January 1,
1998, and December 31, 2002, were retrospectively re-
viewed. Data retrieval and handling were approved by the
institutional review board, and were in accordance with the
corresponding institutional policy manual. Inclusion and
exclusion criteria for this review (Tables I-III) were identi-
cal to those used in the SAPPHIRE trial.4
Postoperative in-hospital mortality, and ipsilateral and
contralateral major stroke rate (functional deficit90 days)
and minor stroke rate (functional deficit 24 hours but
90 days) were determined. Formal postoperative neurol-
ogy consultation was obtained if there was any clinical
suspicion of a neurologic event. The frequency of postop-
erative in-hospital MI was calculated. Major postoperative
bleeding was defined as the need for repeat operation.
Cranial nerve injuries were classified as major (symptomatic
or detectable for 30 days) or minor (asymptomatic and
detectable for 30 days). Two sets of cardiac isoenzymes
(creatinine kinase, troponin) and electrocardiograms were
obtained routinely after operation. Patients were routinely
dismissed from the hospital on the first postoperative day.
Statistical analysis. The 2 or Fisher exact tests, as
appropriate, were used to compare proportions between
high-risk and low-risk groups. Logistic regression models
were used to analyze individual outcome variables (except
death, because of low event rate) and combined outcome
Table I. Criteria for high-risk carotid endarterectomy
High-risk category Criteria
Age (y) 80
Severe cardiac
dysfunction
NYHA class III/IV chronic heart failure
Left ventricular ejection fraction 30%
Open heart surgery within 6 weeks
Myocardial infarction within 4 weeks
NYHA class III/IV angina
Cardiac stress test positive for ischemia
Severe pulmonary
dysfunction
Chronic oxygen therapy
pO2 60 mm Hg
Baseline hematocrit 50%
FEV1 or DLCO 50% of predicted
Local and anatomic
problems
Cervical radiation therapy
Previous ipsilateral carotid
endarterectomy
C2 or higher carotid bifurcation or
division of digastric muscle
Contralateral carotid occlusion
Contralateral laryngeal nerve palsy
NYHA, New York Heart Association; pO2 , partial oxygen pressure; FEV1 ,
forced expiratory volume in 1s; DLCO, diffusing capacity of lung for carbon
monoxide; C2, second cervical vertebra.variables. Univariate logistic regression models were fit for
each variable for each outcome. Results are reported with
odds ratio, 95% confidence interval for odds ratio, and P
value. P  .05 was considered significant for all analyses.
Multivariate analysis was not pursued for any outcomes,
because of low event rate. Some patients underwent more
than one CEA; all procedures were included in the analysis,
and were treated as independent observations.
RESULTS
Data for patients with concomitant intracranial disease
(n  5), acute stoke (n  2), and isolated external CEA (n
 3) were not analyzed. Seven hundred seventy-six CEAs
(716 patients) were included in the main study. Data for
patients (n 121) who would have been excluded from the
SAPPHIRE trial were analyzed separately. Sixty-three per-
cent of the main study population was men; symptoms at
presentation included asymptomatic high-grade stenosis in
73%, hemispheric transient ischemic attack in 22%, and
stroke with minimal residua in 5%. Three-hundred twenty-
three CEAs (42%) were considered high-risk according to
Table II. Criteria for positive cardiac stress test
Exercise stress electrocardiography
Intermediate or high risk Duke treadmill score
Impaired exercise capacity for age and gender
Test-limiting angina
Stress cardiac perfusion scan
Stress-induced reversible perfusion defect or WMA in more
than one vessel territory
Baseline ejection fraction 40% with stress-induced perfusion
defect
Left ventricular enlargement with stress
Increased lung uptake with stress
Pharmacologic or exercise stress echocardiography
Any new WMA with low-dose dobutamine
Stress-induced WMAs in two contiguous segments
Failure of left ventricular systolic cavity to decrease with
dobutamine
Angina in conjunction with new WMA
Stress-induced WMA in combination with ejection fraction
40%
WMA, Wall motion abnormality.
Table III. Criteria for exclusion
Acute stroke (48 h)
Staged elective procedure (within 30 days after CEA)
Elective percutaneous intervention
Contralateral CEA
Other elective operation
Synchronous operation
Common carotid artery angioplasty and stenting or bypass
Cardiac operation
Non-cardiac operation
Intracranial pathology
Intracranial mass
Aneurysm 9 mm
Arteriovenous malformation
Ventriculoperitoneal shunt
CEA, Carotid endarterectomy.
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cases more than one high-risk criterion was present (two
criteria in 9%, three criteria in 1%, four criteria in 1%).
Demographic and clinical data are presented in Table
V. Clinical presentation was similar in the high-risk and
low-risk groups: asymptomatic (73% vs 73%), transient
ischemic attack or amaurosis fugax (23% vs 22%), and
previous stroke (4% vs 5%), respectively. Mean age was
higher (73 vs 70 years; P .0001), and male sex was more
prevalent (67% vs 60%; P  .05) in the high-risk group.
Cardiovascular risk factors including smoking, arterial hy-
pertension, dyslipidemia, and diabetes mellitus were not
statistically different between the high-risk and low-risk
groups. Fifty-five percent of the high-risk group and 44% of
the low-risk group (P  .01) had a history of coronary
artery disease (class II angina, previous MI, percutaneous
or surgical coronary artery revascularization). Overall, 56%
of patients underwent objective cardiac evaluation with a
stress test. Cardiac stress tests were performed more com-
monly in the high-risk group than in the low-risk group
(67% vs 47%; P .0001). Nondiagnostic stress tests, those
performed more than 6 months before CEA, and those
followed by coronary revascularization were not included
in the analysis. In addition to routine duplex ultrasound
scanning, magnetic resonance angiography and catheter
angiography were performed selectively, with catheter an-
giography used more commonly in the high-risk group
(16% vs 11%; P  .05).
General anesthesia was used almost exclusively. Intra-
operative electroencephalograms were obtained in all cases.
Shunting was more frequently necessary in the high-risk
group compared with the low-risk group (22% vs 13%; P
.001). Fifty-six percent of 66 patients with contralateral
carotid occlusion required a shunt. Surgical technique was
similar in the high-risk and low-risk groups; standard end-
arterectomy with patch was used routinely, with eversion
Table IV. Number and frequency of high-risk criteria in
all carotid endarterectomies (n  776)
High-risk criteria n %
Positive cardiac stress test 109 14
Age 80 y 85 11
Contralateral carotid occlusion 66 9
Pulmonary dysfunction 56 7
High carotid bifurcation 36 5
Carotid repeat operation 27 3
LVEF 30%, 11 1.4
NYHA class III/IV CHF 11 1.4
NYHA class III/IV angina 8 1
Cervical radiation therapy 6 1
Recent ( 6 weeks) cardiac
operation
4 1
Contralateral laryngeal nerve palsy 2 1
Recent (4 weeks) MI 1 1
Eighty-four operations were associated with more than one high-risk crite-
ria.
LVEF, Left ventricular ejection fraction; NYHA, New York Heart Associa-
tion; CHF, congestive heart failure; MI, myocardial infarction.endarterectomy performed in selected cases (Table V).
Interposition grafting (four, vein; one, prosthetic) was used
in five patients at high risk (two, repeat operation; two,
cervical radiation therapy; one, high bifurcation). Intraop-
erative completion ultrasound scans were obtained in all
but two patients. Perioperative -blockade was used selec-
tively, based on recommendations made at the preoperative
medical evaluation.
Ipsilateral and contralateral major and minor stroke
rates in patients with symptomatic and asymptomatic dis-
ease, at high and low risk, are presented in Table VI. The
overall stroke rate in 776 patients was 1.4% (symptomatic,
2.9%; asymptomatic, 0.9%). Three of the 11 strokes were
related to acute carotid artery thrombosis, and the others
were considered to have an embolic cause. Differences in
the stroke rate in symptomatic and asymptomatic patients
between the high-risk group (symptomatic, 4.6%; asymp-
tomatic, 0.8%) and low-risk group (symptomatic, 1.6%;
asymptomatic, 0.9%) were not statistically significant. Cer-
vical radiation therapy, New York Heart Association class
III or IV angina, and symptoms at presentation were asso-
ciated with a 15.5-fold, 10.8-fold, and 3.3-fold increase in
stroke, respectively (Table VII). Patients younger than 60
years had 7.7-fold increased stroke rate, although 80% of
these strokes were minor.
Overall mortality was 0.3% (symptomatic, 0.5%;
asymptomatic, 0.2%). The difference in mortality between
the high-risk group (0.6%) and low-risk group (0.0%) was
not significant. The low event rate (n  2) did not allow
Table V. Demographic data and frequency of clinical
variables in patients with high-risk and low-risk CEA
High-risk
(n  323)
Low-risk
(n  453) P
Presentation
Asymptomatic (%) 73 73 NS
TIA or amaurosis fugax (%) 23 22 NS
Stroke (%) 4 5 NS
Demographic data
Mean age (y) 73 70 .0001
Male gender (%) 67 60 .05
Cardiovascular risk factors
Smoking (%) 71 71 NS
Arterial hypertension (%) 88 83 NS
Dyslipidemia (%) 76 81 NS
Diabetes mellitus (%) 24 24 NS
Chronic CAD (%) 55 44 .01
Diagnostic studies
Cardiac stress test (%) 67 47 .0001
Duplex ultrasound
scanning (%)
97 99 NS
MRA (%) 25 22 NS
Angiography (%) 16 11 .05
Operative technique
Shunt (%) 22 13 .001
Patch (%) 87 89 NS
Eversion CEA (%) 2 3 NS
CEA, Carotid endarterectomy; TIA, transient ischemic attack; CAD, coro-
nary artery disease; MRA, magnetic resonance angiography; NS, not signif-
icant).
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death.
Only non-Q-wave (subendocardial) MIs occurred in
the entire series. Postoperative non-Q-wave MI was more
frequent in the high-risk group (3.1%) than in the low-risk
group (0.9%) (P  .05). In addition, a history of coronary
artery disease and a positive cardiac stress test were associ-
ated with 6.5-fold and 3.5-fold increases in the rate of
postoperative non-Q-wave MI, respectively (Table VII).
There was a tendency toward more non-Q-wave MIs in
patients with contralateral carotid occlusion or with New
York Heart Association class III or IV angina.
Differences in the combined major stroke and death
rates between the high-risk and low-risk groups were not
statistically significant (symptomatic, 3.5% vs 0.8%; asymp-
tomatic, 0.4% vs 0.0%, respectively). A composite cluster of
adverse clinical events (death, stroke, MI) was more fre-
quent in the high-risk than in the low-risk symptomatic
group (9.3% vs 1.6%; P .05), but not in the asymptomatic
group (3.4% vs 2.1%; P  .36).
The frequency of other postoperative complications,
including major bleeding (1.9% vs 1.1%), acute carotid
artery thrombosis (0.6% vs 0.7%), cranial nerve injury (7.1%
vs 6.4%), and major cranial nerve injury (1.9% vs 2.0%) was
similar in the high-risk and low-risk groups, respectively.
Patients with high carotid bifurcation, repeat operations,
and previous cervical radiation therapy (local risk factors)
had a 7.7% incidence of cranial nerve injury, which was not
significantly different from the rest of the population
(6.6%). However, there was a trend for more major cranial
nerve injuries in patients with local risk factors (4.6% vs
1.7%; P  .13).
Further analysis was performed on data for CEAs ex-
cluded from the main study (which would have also been
excluded from the SAPPHIRE trial). In this population (n
 121, including 26 CEAs combined with open heart
surgery, 21 combined with supra-aortic great vessel recon-
struction, and 12 bilateral CEAs staged within 30 days) the
postoperative rates for stroke (1.65%; P  .69), death
(1.65%; P  .09), MI (0.83%; P  .71), stroke and death
Table VI. Mean frequency (%) of ipsilateral and contralate
high-risk and low-risk carotid endarterectomy
High-risk
Symptomatic Asymptomatic All Sympto
Ipsilateral
Major stroke 2.3 0.4 0.9 0.8
Minor stroke 2.3 0.4 0.9 0.8
Any stroke 4.6 0.8 1.9 1.6
Contralateral
Major stroke 0.0 0.0 0.0 0.8
Minor stroke 0.0 0.0 0.0 0.0
Any stroke 0.0 0.0 0.0 0.8
Any side
Major stroke 2.3 0.4 0.9 0.8
Minor stroke 2.3 0.4 0.9 0.8
Any stroke 4.6 0.8 1.9 1.6(3.31%; P  .25), and stroke, MI, and death (4.13%; P 
.59) were not statistically different from the corresponding
results in the main study population (n  776).
DISCUSSION
NASCET showed that CEA to treat symptomatic ste-
nosis of 70% or greater is associated with a 17% absolute
ipsilateral stroke risk reduction at 2 years.1 An update of this
trial confirmed a 6.5% absolute 5-year ipsilateral stroke risk
reduction for symptomatic 50% to 69% stenosis, as well.3 In
patients with stenosis of 70% or greater, postoperative
mortality was 0.6% and the stroke and death rate was 5.8%,
and in patients with 50% to 60% symptomatic carotid artery
stenosis, postoperative mortality was 1.2% and the stroke
and death rate was 6.7%. In the ACAS, patients with 60% or
greater asymptomatic carotid artery stenosis had a 6% ab-
solute stroke and death risk reduction over 5 years, associ-
ated with a 2.3% perioperative stroke and death rate, in-
cluding 1.2% angiography-related stroke rate. When
reviewed more carefully, the risk for major stroke and
Table VII. Odds ratios of predictive factors for
postoperative stroke and myocardial infarction at
significance level of P  0.1
Odds ratio
95% Confidence
interval P
Stroke
Age 60 y 7.7 2.3-25.7 .01
Symptomatic presentation 3.3 1-11 .05
Cervical radiation therapy 15.2 1.6-142.2 .05
Class III/IV angina 10.8 1.2-96.4 .05
Myocardial infarction
Contralateral occlusion 3.0 0.8-11.1 .1
History of CAD 6.5 1.4-29.0 .05
Class III/IV angina 8.3 1.0-72.4 .1
Positive cardiac stress test 3.5 1.1-10.7 .05
SAPPHIRE high-risk 3.6 1.1-11.5 .05
CAD, Coronary artery disease; SAPPHIRE, Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy [trial].
roke in symptomatic and asymptomatic patients with
Low-risk Any risk
Asymptomatic All Symptomatic Asymptomatic All
0.0 0.2 1.4 0.2 0.5
0.9 0.9 1.4 0.7 0.9
0.9 1.1 2.9 0.9 1.4
0.0 0.2 0.5 0.0 0.1
0.0 0.0 0.0 0.0 0.0
0.0 0.2 0.5 0.0 0.1
0.0 0.2 1.4 0.2 0.5
0.9 0.9 1.4 0.7 0.9
0.9 1.1 2.9 0.9 1.4ral st
matic
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These landmark studies confirmed the safety and efficacy of
CEA in patients with both symptomatic and asymptomatic
carotid stenosis.
A population-based study of CEA in patients with
symptomatic disease by Hallett et al5 compared favorably
with NASCET, with a 5.1% risk for stroke and death. A
retrospective review of 2228 consecutive patients treated at
The Cleveland Clinic showed an overall risk for stroke and
death of 2.3% (stroke, 1.8%; death, 0.5%) after CEA as an
isolated procedure. Patients undergoing combined CEA
and coronary artery bypass grafting and those undergoing
repeat carotid operations were at significantly higher risk
for this combined end point.8
For a variety of reasons, patients in the NASCET and
ACAS trials were thought to be at low-risk for CEA. Many
patients with significant medical comorbid conditions were
excluded from these trials, in large part to exclude non-
carotid causes of stroke during the follow-up period. These
trial exclusions have been used to cast doubt on the validity
of the conclusions of the respective trials, that they in fact
do not accurately represent the results of CEA in a large
number of patients.9,10 Regardless of where one stands in
this argument, there may be a group of patients who are not
well-served with CEA. A retrospective review from the
Ochsner Clinic found that 46.2% of CEAs in their practice
were in patients ineligible for NASCET or ACAS. The
difference in major stroke and death rate between trial-
eligible (0.5%) and trial-ineligible patients (1.7%) was not
statistically significant, perhaps only because of lack of
statistical power in the study.6 In a large retrospective study
from The Cleveland Clinic, high-risk status was defined by
severe cardiac, pulmonary, or renal dysfunction or by the
need for synchronous operations11 (Table VIII). The rates
of postoperative stroke (3.5% vs 1.7%) and death (4.4% vs
0.3%) were significantly greater in the high-risk group.
When the combined end point of stroke, death, and MI was
evaluated the differences were even greater (7.4% vs 2.9%).
Another, smaller retrospective review with similar defini-
tions of high risk failed to demonstrate a difference in rates
of stroke (2.0% vs 1.9%) and cardiac complication (3.1% vs
1%) between high-risk and low-risk groups.4 Similarly, a
recent report suggests no difference in the risk for stroke
and death between high-risk (1.3%) and low-risk (1.1%)
CEAs12 (Table VIII). Certain anatomic considerations
(previous neck irradiation, high lesions, repeat operations)
have also been identified as high-risk factors at CEA.
CAS is an evolving technique for treatment of carotid
stenosis. Early results of CAS were much inferior to CEA;
these results seem to have improved with the introduction
of low-profile devices, cerebral protection, and better pa-
tient selection.13 Preliminary results of the SAPPHIRE trial
have been released, although they have not yet been sub-
jected to peer review.7 The 30-day risk for death, stroke,
and MI in a group of largely asymptomatic patients was
0.6%, 3.8%, and 2.6%, respectively, in the angioplasty and
stenting group, and 2.0%, 5.3%, and 7.3%, respectively, in
the CEA group. None of these end points, taken separately,reached statistical significance. The combined 30-day
death, stroke, and MI rate was significantly lower in the
endovascular arm (5.8% vs 12.6%), however, largely be-
cause of the substantial difference in non-Q-wave (suben-
docardial) MI favoring the endovascular group. In our
retrospective review of patients who had undergone CEA
the in-hospital risk for death, stroke, and MI was 0.6%,
1.9%, and 3.1%, respectively, in SAPPHIRE-eligible, high-
risk patients, which compares favorably to the early results
of CAS in the SAPPHIRE trial. SAPPHIRE high-risk status
in our experience was associated only with increased post-
operative non-Q-wave MI and with corresponding increase
in the combined outcome variable, which included MI. An
interesting finding in our series was the lack of postopera-
tive transmural MI. This may have been the result of
aggressive perioperative -blockade, which became the
standard of care during the study period, or it may be the
result of the liberal use of cardiac stress tests in selecting
patients for preoperative coronary revascularization.14 We
used general anesthesia almost exclusively; therefore it can
be assumed, on the basis of previous reports, that with more
frequent use of local anesthesia in selected cases further
reduction in cardiac morbidity might be realized.15
Using the SAPPHIRE criteria to define high-risk, we
found no difference in risk for perioperative stroke and
death between high-risk and low-risk groups, regardless of
presentation (symptomatic vs asymptomatic). There was,
however, a significant difference in the rate of perioperative
MI, which was reflected in the combined end point (death,
stroke, MI), favoring the low-risk group, but only in symp-
tomatic patients. These findings mirror those of the SAP-
PHIRE preliminary results; in addition, all MIs in our
patients, who routinely had assessment of cardiac isoen-
zymes postoperatively, were non-Q-wave MIs. The impli-
cation of these “chemical” MIs over the long term is
uncertain. The lack of any Q-wave MIs in this series seems
to justify our practice of routine preoperative cardiac risk
stratification based on formal medical evaluation by a car-
diologist or vascular medicine specialist and frequent acqui-
sition of cardiac stress tests. When evaluating the local risk
factors of repeat operation, high internal carotid lesions,
and previous cervical irradiation, there was a tendency
toward more major cranial nerve injuries, which did not
reach statistical significance; these findings are intuitive.
When looking at a variety of outcome variables, irre-
spective of SAPPHIRE inclusion or exclusion, we identified
several risk factors that did significantly increase the risk for
perioperative stroke, including previous cervical irradiation,
severe angina pectoris, symptomatic presentation, and age
younger than 60 years. Of no surprise, patients with a
history of coronary artery disease and positive stress tests
were at statistically significant increased risk for periopera-
tive non-Q-wave MI. The increase in postoperative stroke
rate in our young (60 years) patients is puzzling, even
though most of these strokes (80%) were minor. In a
statewide analysis of 9918 CEAs the postoperative stroke
rate was 1.7% in patients younger than 65 years, which was
not significantly different from the older patient cohort.16
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Volume 39, Number 5 Mozes et al 963Table VIII. Definition of high-risk CEA: Major exclusion criteria for NASCET and ACAS, and major inclusion criteria
for population-based studies of high-risk CEA and SAPPHIRE
Exclusion criteria Inclusion criteria
NASCET ACAS
Ouriel et al,
2001
Jordan et al,
2002
Gasparis et al,
2003 SAPPHIRE
Age (y) 79 79 80 80
History Contralateral CEA
4 mo
Major surgical
procedure 1 mo
Major vascular
procedure 1 mo
Major surgical
procedure 1 mo
Stroke in evolution
Stroke in evolution
Comorbidities
Cardiac Unstable angina Unstable angina PTCA or
CABG
6 mo
Coronary procedure
1 mo
NYHA
III/IV
Open heart surgery
6 wk
Atrial fibrillation Atrial fibrillation Canadian
CVA heart
failure
MI 4 wk
Valvular heart
disease
Valvular heart disease History
of CHF
CABG 6 wk functional
class III/IV
Angina CCS class
III/IV
Symptomatic
CHF
Symptomatic CHF Angina, NYHA
III/IV
CABG
6 mo
CHF class III/IV
MI 6 mo EF 30% EF 30%
MI 4 wk Abnormal cardiac
stress test
Pulmonary Lung failure Lung failure with
effect on 5-year
survival
Severe
COPD
FEV1 1 L Steroid
dependency
Long-term oxygen
therapy
Home oxygen Oxygen
dependency
Resting pO2 60
mm Hg
Baseline hematocri
50%
Renal Kidney failure Creatinine 3 Creatinine
3
Creatinine
3
FEV1 or DLCO
50% predicted
Other Uncontrolled HTN BP (mm Hg) 180,
systolic, 115,
diastolic
Uncontrolled DM Fasting glucose 400
Liver failure Liver failure
Cancer, 50%
5-year survival
Cancer, 50% 5-year
survival
Active ulcer disease
Warfarin sodium
Anatomic
criteria
Previous ipsilateral
CEA
Previous ipsilateral CEA Previous ipsilateral
CEA
Previous
ipsilateral
CEA
Previous ipsilateral
CEA
Tandem lesion
greater than
target stenosis
Tandem lesion greater
than target stenosis
Cervical radiation
treatment
Cervical
radiation
treatment
Severe tandem
lesion
Cervical radiation
treatment
Contralateral carotid
occlusion
Contralateral
carotid
occlusion
Cervical radiation
treatment
Contralateral
carotid occlusion
High cervical lesion High
cervical
lesion
High cervical
lesion (at least
C2)
Lesion below clavicle Lesion below
clavicle
Contralateral
laryngeal palsy
CEA, Carotid endarterectomy; SAPPHIRE, Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy [trial]; CHF, chronic heart
failure; MI, myocardial infarction; HTN, hypertension; DM, diabetes mellitus; BP, blood pressure; PTCA, percutaneous transluminal coronary angioplasty;
CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; Canadian CVA, Canadian
Cardiovascular Association; CCS, Canadian Cardiovascular Society; EF, ejection fraction; pO2 , partial oxygen pressure; FEV1, forced expiratory volume in 1 s;
DLCO, diffusing capacity of lung for carbon monoxide; C2, second cervical vertebra.
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rotid artery disease may represent a population with prema-
ture atherosclerosis, unrecognized hypercoagulable disor-
ders, or labile plaques predisposing to postoperative
embolic complications. Carotid stenosis in these patients
may simply be a marker for more severe atherosclerosis seen
in young patients. At the other end of the age spectrum,
patients older than 80 years did not demonstrate increased
risk for postoperative stroke and death in this series.
Contralateral carotid artery occlusion did not have a
significant effect on postoperative stroke and death in our
experience. CEA with liberal use of selective shunting
resulted in similar excellent outcome in earlier studies, as
well.17,18
The long-term benefit of carotid artery revasculariza-
tion in asymptomatic patients at high medical risk is con-
troversial. The relatively modest reduction in stroke risk in
ACAS, which became apparent only after 5 years, suggests
that asymptomatic patients with limited survival may not
enjoy any benefit. Stroke risk reduction increased with the
severity of stenosis in NASCET, but not in ACAS.1,2 As
such, for patients at prohibitive medical risk we typically
recommend CAS for critical carotid stenosis in asymptom-
atic patients and for symptomatic patients who have failed
medical therapy. Patients with limited life expectancy are
frequently treated expectantly, especially if they have
asymptomatic disease.
Although this series represents a consecutive group of
patients undergoing CEA, its limitations are related to its
retrospective nature. Postoperative complication rates are
in-hospital values, which may be lower than 30-day results.
Without an evaluation by an independent neurologist, the
recognition of cerebrovascular events, minor events in par-
ticular, remained subjective and dependent on variations in
the scrutiny of the postoperative examination. Similarly,
minor cranial nerve injuries may have been missed or sub-
jectively misinterpreted. Another source of variation is that
perioperative care changed during the study period as peri-
operative -blockade became more popular. Direct com-
parison of our results with those of the SAPPHIRE trial is
limited by the possible differences in the distribution of
individual high-risk criteria in the two studies. Our popu-
lation had a somewhat higher percentage of patients with-
out symptoms, compared with the SAPPHIRE trial (73% vs
66%). In addition, some inclusion criteria for SAPPHIRE
eligibility, such as advanced age and contralateral carotid
occlusion, may not have a significant effect on immediate
postoperative outcome.
CONCLUSION
CEA can be performed with very low morbidity and
mortality, even in SAPPHIRE-eligible patients at high risk.
In the setting of surgical results such as these, the role of
CAS in patients at high risk remains undefined. When taken
in aggregate, the SAPPHIRE criteria are not predictive of
perioperative stroke; they are predictive of perioperative
non-Q-wave MI. When evaluating the combined end pointof stroke, death, and MI, patients at high risk with symp-
tomatic disease are at increased risk, largely on the basis of
increased risk for non-Q-wave MI; patients with asymp-
tomatic disease are not. Patients with local risk factors
(repeat operation, high bifurcation, radiation therapy) tend
to have more major cranial nerve injuries.
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Available online Mar 8, 2004.Dr Dennis Fry (Iowa City, Ia). I just have two questions.
First, you said that you do stress tests in all your patients. Does that
change your approach in the 35% of symptomatic patients? For
instance, do they go to coronary bypass or do they go to angio-
plasty and stenting before undergoing carotid endarterectomy?
And then my second question, which is more of a comment, is that
there was an article recently by Kim et al in Circulation in 2002,
and they stated there was a sixfold increase in mortality for non-
Q-wave MIs, and it sounded like you were suggesting that non-
Q-wave MIs didn’t matter that much.
Dr Geza Mozes. Regarding the first question, one of the
inclusion criteria in the SAPPHIRE trial was having a preoperative
positive stress test; therefore, in this study, in the high-risk group,
we included only those patients with a positive stress test who did
not have an intervention between the positive stress test and the
carotid endarterectomy. If the cardiac stress test is highly positive,
then our patients routinely undergo percutaneous coronary revas-
cularization.
The other question recalls a very, very important issue, and
comes up repeatedly in this discussion. One thing we have to ask at
first is, Do you think that having a subendocardial MI is the cause
of a future death, or is it just an indicator, a sort of stress test, that
points to a population with poor cardiac prognosis?
Dr Iraklis Pipinos (Omaha, Neb). This is certainly important
data that will influence our daily decision-making. The SAPPHIRE
trial reported a significantly higher non-Q-wave MI rate in their
patients having carotid endarterectomies. Of interest, it was that
higher rate, around 5% to 6%, that made their 30-day combined
death, stroke, and MI rates significantly worse in the endarterec-
tomy patients compared with the patients receiving angioplasty
and stenting. What do you think accounts for the difference
between their non-Q-wave MI rate and the one you observed in
your series?
Dr Mozes. It is a good question. First of all, one should
assume in this retrospective study that we may have overlooked a
few minor events. However, I mentioned during the talk that it is
our policy to check troponin after every single endarterectomy;
therefore our sensitivity may have been quite reasonable. I don’t
have a good explanation why our results are better. We follow usual
rules by applying aggressive -blockade and extensive preoperativestudies it is very difficult to compare them face to face. The
SAPPHIRE trial was a relatively small study, so what we are seeing
here may be just a statistical variation.
Dr Donald Jacobs (St Louis, Mo). I would take a different
bent on your data, to say that you just have reaffirmed the findings
of the SAPPHIRE trial, that is, these patients do have increased risk
for non-Q-wave MI. Whether that is significant or not could be
debated. Also, the risk of stroke, although statistically not different,
may be a number that would be significant in larger numbers, a
larger study. I think that again they are not that different, the
high-risk stroke rate in your hands and the ones that were in the
SAPPHIRE trial. I’m not sure I would take the same approach that
shows that these patients are not at high risk. But indeed there is a
difference, and the results are not that greatly different from the
SAPPHIRE data. I wonder what your comments are on that.
Dr Mozes. I agree that there are several different ways to look
at the same set of data. The question is, Where do you want to put
the emphasis? I think that we should emphasize that SAPPHIRE-
eligible status should not necessarily be an indication for carotid
artery stenting. What we suggest is that it would not be correct to
submit 42% of the whole population to carotid artery stenting,
based on the preliminary data of the SAPPHIRE trial. On the other
hand, I agree that if we look at the symptomatic high-risk patients,
which is a much smaller population, about 15% of the entire
population, then you can make an argument that those patients, at
least in the short run, will do better with stenting. Indeed, that
pretty much describes our practice; in addition to the patients with
local risks, the patients who are symptomatic and have very high
medical risk are those to whom we recommend stenting. Again, if
you put all of these numbers together, that will be about 15% of the
population, and not 42%. This is the point of this study.
Dr Timothy Sullivan. I would just like to make a brief
comment, as the senior author of the paper, that the idea is not to
condemn carotid angioplasty and stenting. Simply stated, perhaps
we need to raise the bar a little bit in terms of comparing angio-
plasty and stenting in high-risk patients with endarterectomy in
high-risk patients. The idea is not that angioplasty and stenting has
to meet a standard of 6% risk for stroke and death in symptomatic
patients, and 2% or 3% in asymptomatic patients, but in fact the bar
is substantially higher than that. Carotid endarterectomy remains
the gold standard for most patients, whether high or low risk.INVITED COMMENTARYIn an ongoing effort to refine indications for carotid endarter-
ectomy (CEA), multiple investigators have attempted to define
“high-risk” subgroups in which the outcomes of CEA are worse
than generally expected. The hypothesis has been that carotid
artery stenting (CAS) would be preferable in such patients. The
SAPPHIRE trial, completed in 2002 but not yet published, is an
effort to test this hypothesis in a prospective randomized trial.Results, presented in abstract form, are sobering for advocates of
CEA and CAS alike.
In this issue of the JVS, Mozes et al present the latest of several
single-institution retrospective reviews in which patients were di-
vided into normal- and high-risk categories on the basis of criteria
used in “high-risk” trials such as SAPPHIRE.1-3 Their results, like
those of other surgical series, fail to show different outcomes
